Nasdaq
$1.36▲ 2.26%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $236.1MShares out 1.700M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 3d agoAfter-hours26.10.22 06:444Ownership#●●●
PALISADE BIO, INC.
Julien E. Capers, an insider at Palisade Bio, Inc., filed a Form 4 report on October 21, 2026, regarding a change in beneficial ownership of securities effective October 19, 2026. This filing serves as an official disclosure of the insider's updated equity position.…more
$1.36+2.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 3d agoAfter-hours26.10.22 06:073Ownership
PALISADE BIO, INC.
Julien E. Capers, an insider of Palisade Bio, Inc., filed a Power of Attorney on October 21, 2026, to facilitate compliance with Section 16 reporting requirements. The document authorizes John David Finley and Ryker Willie to prepare and file necessary forms, including Forms 3, 4, and 5, regarding the insider's ownership and transactions in company securities.…more
$1.36+2.26%vs prev closeView filingShare - 10.8Overnight26.10.08 10:354Ownership
PALISADE BIO, INC.
Insider Jones Mitchell Lawrence filed a Form 4 with the SEC on October 7, 2026, reporting a change in beneficial ownership of securities for Palisade Bio, Inc. as of October 6, 2026.…more
$1.36+2.26%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 4d agoPre-market26.10.20 21:05#●●●#●●●
Palisade Bio Presents Clinical Data for PALI-2108 in IBD at UEG Week
Palisade Bio reported early clinical data for its IBD candidate PALI-2108, showing endoscopic improvement and reduced inflammation in small patient cohorts. These exploratory findings require confirmation through larger, controlled clinical trials currently in progress.…more
$1.36+2.26%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.12Pre-market26.10.12 21:05
●●●●●●●● ●●●●● ●●●●●●
Palisade Bio presented new clinical data for its PALI-2108 candidate in ulcerative colitis and Crohn’s disease, supporting its ongoing Phase 2 development. These findings are based on small, open-label studies, and the company notes that larger trials are required to confirm efficacy.…more
$1.36+2.26%vs prev close - 9.28Pre-market26.09.28 21:50
●●●●●●●● ●●●●● ●●●●●●
Palisade Bio will present Phase 1b clinical and translational data for its lead candidate PALI-2108 at the upcoming UEG Week 2026. The presentations will highlight the drug's safety, tolerability, and early clinical activity in patients with inflammatory bowel disease.…more
$1.36+2.26%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report